AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates

Core Viewpoint - AbbVie reported quarterly earnings of $1.86 per share, exceeding the Zacks Consensus Estimate of $1.77 per share, but down from $3 per share a year ago, indicating a significant year-over-year decline in earnings [1][2] Financial Performance - AbbVie achieved revenues of $15.78 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.20% and showing an increase from $14.46 billion in the same quarter last year [2] - The company has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - AbbVie shares have increased approximately 28.4% since the beginning of the year, outperforming the S&P 500's gain of 16% [3] - The immediate price movement of AbbVie’s stock will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $3.33, with expected revenues of $16.32 billion, and for the current fiscal year, the EPS estimate is $10.80 on revenues of $60.68 billion [7] - The estimate revisions trend for AbbVie was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of AbbVie’s stock may also be influenced by the overall outlook for the industry [8]